TRAF2蛋白酶体降解介导多柔比星心肌病线粒体功能障碍
该研究结合多柔比星处理的小鼠体内实验与乳鼠、小鼠及人诱导多能干细胞来源心肌细胞体外实验,发现多柔比星通过cIAP1与USP19互作促使TRAF2蛋白酶体降解,导致RIPK1的K63连接多泛素化丢失、TNFα介导的NF-κB活化受损,从而增加心肌细胞坏死死亡。恢复TRAF2可保护线粒体功能与心脏功能。
要点
- 多柔比星使心肌TRAF2蛋白经蛋白酶体降解,破坏TNFα-NF-κB存活信号。
- cIAP1与USP19互作调控TRAF2降解,干预此轴可减少多柔比星诱导的心肌细胞死亡。
- 心肌限制性表达TRAF2可保护多柔比星所致线粒体缺陷与心功能障碍。
核心结论
- 多柔比星通过蛋白酶体降解TRAF2破坏TNFα-NF-κB存活通路,使心肌细胞对TNFα介导的坏死性细胞死亡敏感,从而参与多柔比星心脏毒性。
研究设计与样本
- 研究采用C57/BL6J小鼠每周注射多柔比星5 mg·kg-1·wk-1共4次的体内实验,以及大鼠、小鼠和人诱导多能干细胞来源心肌细胞的体外实验。
主要发现
- 与溶媒处理小鼠相比,多柔比星处理小鼠心脏出现胞质肿胀、线粒体异常及TNFα水平升高。
- 多柔比星处理的心肌细胞中TNFα介导的NF-κB活化受损,伴随TRAF2蛋白酶体降解所致RIPK1的K63连接多泛素化丢失。
- 接受多柔比星治疗的癌症患者心脏中TRAF2蛋白丰度显著降低。
- cIAP1(H588A)E3连接酶突变体或USP19功能获得可阻止TRAF2蛋白酶体降解及多柔比星诱导的细胞死亡。
- 野生型TRAF2而非缺陷RIPK1 K63连接多泛素化的RING指突变体可恢复NF-κB信号并抑制多柔比星诱导的心肌细胞死亡。
临床怎么用
- 提示TRAF2-NF-κB通路可能作为减轻多柔比星心脏毒性的潜在干预靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cytokines such as tumor necrosis factor-α (TNFα) have been implicated in cardiac dysfunction and toxicity associated with doxorubicin (DOX). Although TNFα can elicit different cellular responses, including survival or death, the mechanisms underlying these divergent outcomes in the heart remain cryptic. The E3 ubiquitin ligase TRAF2 (TNF receptor associated factor 2) provides a critical signaling platform for K63-linked polyubiquitination of RIPK1 (receptor interacting protein 1), crucial for nuclear factor-κB (NF-κB) activation by TNFα and survival. Here, we investigate alterations in TNFα-TRAF2-NF-κB signaling in the pathogenesis of DOX cardiotoxicity. METHODS: Using a combination of in vivo (4 weekly injections of DOX 5 mg·kg-1·wk-1) in C57/BL6J mice and in vitro approaches (rat, mouse, and human inducible pluripotent stem cell-derived cardiac myocytes), we monitored TNFα levels, lactate dehydrogenase, cardiac ultrastructure and function, mitochondrial bioenergetics, and cardiac cell viability. RESULTS: In contrast to vehicle-treated mice, ultrastructural defects, including cytoplasmic swelling, mitochondrial perturbations, and elevated TNFα levels, were observed in the hearts of mice treated with DOX. While investigating the involvement of TNFα in DOX cardiotoxicity, we discovered that NF-κB was readily activated by TNFα. However, TNFα-mediated NF-κB activation was impaired in cardiac myocytes treated with DOX. This coincided with loss of K63- linked polyubiquitination of RIPK1 from the proteasomal degradation of TRAF2. Furthermore, TRAF2 protein abundance was markedly reduced in hearts of patients with cancer treated with DOX. We further established that the reciprocal actions of the ubiquitinating and deubiquitinating enzymes cellular inhibitors of apoptosis 1 and USP19 (ubiquitin-specific peptidase 19), respectively, regulated the proteasomal degradation of TRAF2 in DOX-treated cardiac myocytes. An E3-ligase mutant of cellular inhibitors of apoptosis 1 (H588A) or gain of function of USP19 prevented proteasomal degradation of TRAF2 and DOX-induced cell death. Furthermore, wild-type TRAF2, but not a RING finger mutant defective for K63-linked polyubiquitination of RIPK1, restored NF-κB signaling and suppressed DOX-induced cardiac cell death. Last, cardiomyocyte-restricted expression of TRAF2 (cardiac troponin T-adeno-associated virus 9-TRAF2) in vivo protected against mitochondrial defects and cardiac dysfunction induced by DOX. CONCLUSIONS: Our findings reveal a novel signaling axis that functionally connects the cardiotoxic effects of DOX to proteasomal degradation of TRAF2. Disruption of the critical TRAF2 survival pathway by DOX sensitizes cardiac myocytes to TNFα-mediated necrotic cell death and DOX cardiotoxicity.
引用
- Dhingra R, Rabinovich-Nikitin I, Rothman S, et al. Proteasomal Degradation of TRAF2 Mediates Mitochondrial Dysfunction in Doxorubicin-Cardiomyopathy. Circulation. 2022. PMID: 35983756. doi:10.1161/CIRCULATIONAHA.121.058411
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。